Form 4: Moderna's Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Shannon Thyme Klinger, Moderna's Chief Legal Officer, reports the vesting of performance-based restricted stock units and subsequent tax withholding.
Summary
- On February 12, 2025, Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported transactions involving Moderna's common stock.
- 2,047 shares were acquired through the vesting of performance-based restricted stock units (PSUs) granted on March 1, 2022.
- 1,068 shares were disposed of to satisfy tax withholding obligations related to the vesting of these PSUs at a price of $30.93.
- Following these transactions, Klinger directly owns 21,425 shares of Moderna's common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an officer, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.
Key Dates
| Date | Description |
|---|---|
| March 1, 2022 | Date of grant for the performance-based restricted stock units (2022 PSUs). |
| February 12, 2025 | Date of stock transactions: vesting of PSUs and tax withholding. |
| February 14, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.